| Literature DB >> 26075287 |
Francesca Ingegnoli1, Roberta Gualtierotti1, Annalisa Orenti2, Tommaso Schioppo3, Giovanni Marfia4, Rolando Campanella4, Claudio Mastaglio5, Pier Luigi Meroni1, Patrizia Boracchi2.
Abstract
In patients with Raynaud's phenomenon (RP), the role of medical history, capillaroscopy, and autoantibodies in order to provide an early diagnosis of connective tissue disease (CTD) were examined. 115 consecutive adults with uni-, bi-, or triphasic colour changes of the fingers were studied. RP was bilateral in 92.7% of patients. The middle finger was significantly more affected. A lack of association between fingers affected by RP and fingers with capillary abnormalities was observed OR = 0.75 (0.34-1.66). RP with the cyanotic phase had a higher risk at capillaroscopy to have hemorrhages OR = 4.46 (1.50-13.30) and giant capillaries OR = 24.85 (1.48-417.44). The thumb and triphasic involvement have an OR of 1.477 and 1.845, respectively. RP secondary to systemic sclerosis (SSc) had greater value of VAS pain (p = 0.011). The presence of anti-centromere antibodies was significantly associated with a higher risk of SSc (p < 0.001). 44.3% of subjects had uniphasic blanching of the fingers, and among these, 27% was diagnosed as having an overt or suspected CTD. Markers of a potential development of CTDs include severe RP symptoms, positive autoantibodies, and capillary abnormalities. These data support the proposal to not discharge patients with uniphasic blanching of the fingers to avoid missing the opportunity of an early diagnosis.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26075287 PMCID: PMC4449942 DOI: 10.1155/2015/371960
Source DB: PubMed Journal: J Immunol Res ISSN: 2314-7156 Impact factor: 4.818
Demographic data, clinical features, and diagnostic investigations of the study cohort.
| Primary RP | RP secondary to suspected CTD | Systemic sclerosis* | |
|---|---|---|---|
| Number of subjects | 39 | 55 | 20 |
| Female number (%) | 38 (97.4%) | 51 (92.7%) | 15 (75%) |
| Age median (IQR) years | 44.8 (31.7–53.8) | 42.4 (31.3–52.9) | 58.2 (47.2–68.8) |
| RP duration median (IQR) years | 5 (1.8–10) | 3 (1.1–10) | 2 (1.3–3) |
| RP bilateral number (%) | 36 (92.3%) | 47 (94%) | 18 (90%) |
| Number of fingers with RP median (IQR) | 8 (6–10) | 8 (6–10) | 8 (7.5–10) |
| Thumb affected by RP | 15 (38.5%) | 22 (44%) | 7 (35%) |
| Uniphasic RP number (%) | 17 (43.7%) | 20 (36.3%) | 11 (55%) |
| (i) White number (%) | 15 (38.5%) | 19 (34.5%) | 10 (50%) |
| (ii) Blue number (%) | 1 (2.6%) | 1 (1.8%) | 1 (5%) |
| (iii) Red number (%) | 1 (2.6%) | 0 (0%) | 0 (0%) |
| Biphasic RP number (%) | 18 (46.1%) | 29 (52.8%) | 5 (25%) |
| (i) White/blue number (%) | 2 (5.1%) | 4 (7.3%) | 3 (15%) |
| (ii) White/red number (%) | 16 (41%) | 25 (45.5%) | 2 (10%) |
| (iii) Blue/red number (%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Triphasic RP number (%) | 2 (5.1%) | 6 (10.9%) | 4 (20%) |
| VAS pain median (IQR) | 12 (1–45) | 13 (0–41.25) | 40 (6.1–47.4) |
| VAS severity median (IQR) | 13 (4–47.5) | 15 (0–36.5) | 9 (0–37) |
| VAS discomfort median (IQR) | 2 (0.5–6.5) | 3 (0–5) | 3 (1–5.5) |
| ANA positivity number (%) | 0 (0%) | 29 (52.7%) | 17 (85%) |
| Anti-ENA positivity number (%) | 0 (0%) | 22 (40%) | 17 (85%) |
| Antigen | 7 CENP A and B | 8 CENP A and B | |
| 8 Ro52 | 2 Scl70 | ||
| 2 Scl-70; 1 Th/To | 3 Ro52; 3 PM100 | ||
| 2 PM75; 2 Ku; | 1 Th/To; 1 Ku; | ||
| 3 PL7; 1 OJ; 1 EJ | 1 RP155; 1 PL7 | ||
| Capillaroscopy abnormal number (%) | 0 (0%) | 6 (10.9%) | 16 (80%) |
*In our cohort, all the patients with sRP were diagnosed as systemic sclerosis.
RP: Raynaud phenomenon; CTD: connective tissue disease; IQR: interquartile range; ANA: anti-nuclear antibodies; anti-ENA: antiextractable nuclear antigen; VAS: visual analogue scale.
Univariate analysis of primary RP versus RP secondary to suspected connective tissue disease. All the variables included as mandatory in the classification criteria of primary RP (i.e., ANA and capillaroscopy that must be negative) were excluded from the analysis.
| Primary RP versus RP secondary to suspected connective tissue disease | ||
|---|---|---|
| OR (95% CI) |
| |
| RP duration (years) | 0.999 (0.995–1.003) | 0.688 |
| Number of fingers affected by RP | 1.031 (0.846–1.255) | 0.764 |
| Thumb affected by RP | 1.477 (0.535–4.078) | 0.452 |
| Number of RP colour phases | 1.845 (0.864–3.94) | 0.114 |
| VAS pain | 0.996 (0.975–1.018) | 0.742 |
| VAS severity | 0.997 (0.978–1.016) | 0.756 |
| VAS discomfort | 0.964 (0.821–1.133) | 0.659 |
RP: Raynaud phenomenon; OR: odds ratio; CI: confidence interval; VAS: visual analogue scale.
Univariate analysis of Raynaud's phenomenon secondary to a suspected connective tissue disease versus systemic sclerosis (A) and association of different variables assessed by binomial logistic regression (B).
| RP suspected secondary to a connective tissue disease versus systemic sclerosis | ||
|---|---|---|
| OR (95% CI) |
| |
| (A) Univariate analysis | ||
| RP duration (years) | 0.993 (0.984–1.002) | 0.133 |
| Number of fingers affected by RP | 1.04 (0.843–1.284) | 0.713 |
| Thumb affected by RP | 0.587 (0.192–1.795) | 0.351 |
| Number of RP colour phases | 0.634 (0.279–1.438) | 0.275 |
| VAS pain | 1.011 (0.99–1.033) | 0.305 |
| VAS severity | 0.996 (0.975–1.018) | 0.738 |
| VAS discomfort | 1.079 (0.889–1.309) | 0.443 |
| ANA positive (nonanticentromere) versus ANA negative | 2.652 (0.61–11.518) | 0.193 |
| ANA positive (anticentromere) versus ANA negative | 25 (4.248–147.122) | <0.001 |
|
| ||
| (B) Binomial logistic regression | ||
| VAS pain | 1.067 (1.015–1.122) | 0.011 |
| VAS severity | 0.955 (0.912–0.999) | 0.049 |
| ANA positive (nonanticentromere) versus ANA negative | 2.456 (0.499–12.088) | 0.269 |
| ANA positive (anticentromere) versus ANA negative | 49.023 (6.566–366.005) | <0.001 |
RP: Raynaud phenomenon; ANA: anti-nuclear antibodies; VAS: visual analogue scale; OR: odds ratio; CI: confidence interval.